Institutional Biosafety Committee

May 30, 2025 | Required Policies

IBC Meeting Minutes IBC minutes 072126 IBC Minutes 052225_Redacted IBC Roster IBC contacts...

MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine

Jan 24, 2025 | Press Releases

HDT Bio’s LION™ platform to support malaria vaccine development by MalarVx SEATTLE, Jan. 15, 2025 /PRNewswire/ — MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio’s proprietary self-amplifying replicon RNA...

Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68

Nov 13, 2024 | In the News

Click here to view...

Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines

Sep 19, 2024 | In the News

Click here to view...

HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative

Sep 17, 2024 | Press Releases

HDT bio’s Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ — HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies,...